Related Experiment Video
Updated: Aug 5, 2026

Assessment of DNA Double Strand Break Repair Activity Using High-throughput and Quantitative Luminescence-Based Reporter Assays
Published on: June 14, 2024
The DNA damage response and cancer immunotherapy
Sheng Hong1,2, Guo-Min Li3,4,5
1Chinese Institute for Cancer Research, Chinese institutes for Medical Research, Beijing, China.
Abstract:
The DNA damage response (DDR) and immune system serve as critical defence mechanisms, safeguarding genomic integrity and providing host protection, respectively. Emerging research reveals their interconnection in dictating the response to cancer immunotherapy. DDR-deficient tumours or those exposed to DDR inhibitors display genomic instability that generates two key immunogenic signals: neoantigens that activate tumour-specific T cells; and cytosolic DNA that stimulates the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, triggering type I interferon production and immune cell recruitment. These synergistic effects drastically enhance responsiveness to immune checkpoint blockade. This Review examines the molecular mechanisms by which DDR defects potentiate immunotherapy, including recent advances in DDR-targeted combination strategies. We further analyse resistance mechanisms and discuss innovative approaches to overcome therapeutic limitations, offering a comprehensive perspective on exploiting DDR deficiencies for improved cancer treatment outcomes.
Insights
DNA damage response (DDR) defects in cancer immunotherapy enhance immune response by generating immunogenic signals. This review explores how targeting DDR deficiencies can improve cancer treatment outcomes.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- The DNA damage response (DDR) and immune system are crucial for genomic integrity and host defense.
- Their interplay is increasingly recognized as vital for cancer immunotherapy efficacy.
Purpose of the Study:
- To review the molecular mechanisms linking DDR defects to enhanced immunotherapy response.
- To discuss advances in DDR-targeted combination strategies and resistance mechanisms.
Main Methods:
- Literature review of emerging research on DDR and cancer immunotherapy.
- Analysis of molecular pathways involving genomic instability, neoantigens, and the cGAS-STING pathway.
- Examination of clinical implications and therapeutic strategies.
Main Results:
- DDR-deficient tumors or those treated with DDR inhibitors exhibit genomic instability, producing neoantigens and cytosolic DNA.
- This stimulates the cGAS-STING pathway, increasing type I interferon and immune cell recruitment.
- These effects synergize to improve responsiveness to immune checkpoint blockade.
Conclusions:
- Exploiting DDR deficiencies offers a promising strategy to potentiate cancer immunotherapy.
- DDR-targeted combination therapies and overcoming resistance are key to improving treatment outcomes.
Related Concept Videos
Tumor Immunotherapy
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Overview of DNA Repair
Chemically...
Overview of DNA Repair
Chemically...

